İLERİ EVRE/REKÜREN OVER KANSERİ NEDENİYLE HİPERTERMİK İNTRAPERİTONYAL KEMOTERAPİ (HIPEC) UYGULADIĞIMIZ HASTALARDAKİ PEROPERATİF TECRÜBEMİZ Our Peroperative Experience in Patients who Underwent Hyperthermic Intraperitoneal Chemotherapy (Hipec) For Advanced Stage/Recurrent Ovarian Cancer

Year 2019, Volume: 9 Issue: 3, 65 - 69, 16.09.2019

Oğuzhan Kuru , Mehmet Gökçü

Abstract

ÖZET

Amaç: İleri evre/reküren over kanseri nedeniyle sitoredüktif cerrahi ve Hipertermik İntraperitonyal Kemoterapi

(HIPEC) uyguladımız hastalardaki peroperatif morbidite ve mortaliteyi araştırdık.

Yöntem: Ocak 2016-Aralık 2018 tarihleri arasında HIPEC uyguladığımız hastaların elektronik dosyaları ve takipleri

retrospektif olarak incelendi.

Bulgular: Nihai patolojisi musinöz apandiks tümörü gelen 1 vaka dışlandığında peritonyal karsinomatozis nedeniyle

toplam 18 hastaya ileri cerrahi ve HIPEC uygulandı. Hastaların ortalama yaşı 54,6 (aralık, 22-76 yaş)

idi. Median preoperatif CA125 değeri 64 U/ml (aralık, 6-4756 U/ml) idi. 3 hasta rekürens nedeniyle, 15 hasta

(11 interval, 4 first-look cerrahi) ise primer olarak opere edildi. Hastaların hepsine peritonektomi prosedürü,

4 hastaya ise beraberinde barsak rezeksiyonu uygulandı. Ortalama operasyon süresi 323,5 dakika (aralık, 180-

495 dakika) idi. En sık gözlenen dahili morbidite, kan transfüzyonu (83.3%, 15/18); cerrahi morbidite ise yara

yeri enfeksiyonu (%16.6, 3/18) bulundu. Hastaların ortalama hastanede yatış süresi 10,3 gün (aralık, 5-32 gün)

idi. Peroperatif mortalite gözlenmedi.

Sonuç: HIPEC, yoğun bakım koşulları iyi olan ve multidisipliner kliniklerde uygulandiğında peroperatif ciddi

morbidite ve mortaliteye neden olmayan bir yöntemdir.

Anahtar Sözcükler: HIPEC; Peroperatif; Morbidite.

ABSTRACT

Objective: We investigated peroperative morbidity and mortality in patients who underwent cytoreductive

surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced stage/recurrent ovarian

cancer.

Methods: Between January 2016 and December 2018, electronic files and follow-up of patients who

underwent HIPEC were reviewed retrospectively.

Results: After one case of mucinous appendiceal tumor was excluded, a total of 18 patients underwent

advanced surgery and HIPEC due to peritoneal carcinomatosis were detected. The mean age of the patients

was 54.6 years (range, 22-76 years). The median preoperative CA125 value was 64 U/ml (range 6-4756 U/

ml). Fifteen patients (11 interval surgeries, 4 first-look surgeries) were operated primarily while 3 patients

were operated due to recurrent disease. Peritonectomy procedure was performed in all patients and bowel

resection was performed in 4 patients. The mean operative time was 323.5 minutes (range, 180-495 minutes).

The most common medical morbidity was blood transfusion (83.3%, 15/18) while most common surgical

morbidity was wound infection (16.6%, 3/18). The mean length of hospitalization was 10.3 days (range, 5-32

days). No peroperative mortality was observed.

Conclusion: HIPEC is a method that does not cause severe morbidity and mortality when well intensive care

conditions are applied in multidisciplinary clinics.

Keywords: HIPEC; Peroperative; Morbidity.

Keywords

İLERİ EVRE/REKÜREN OVER KANSERİ NEDENİYLE HİPERTERMİK İNTRAPERİTONYAL KEMOTERAPİ (HIPEC) UYGULADIĞIMIZ HASTALARDAKİ PEROPERATİF TECRÜBEMİZ Our Peroperative Experience in Patients who Underwent Hyperthermic Intraperitoneal Chemotherapy (Hipec) For Advanced Stage/Recurrent Ovarian Cancer

References

• 1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. 2. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138–50. 3. Chua TC, Moran B, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early and long-term outcome data on 2298 patients with pseudomyxoma peritonei of appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–56. 4. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O,et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–42. 5. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy:retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63–8. 6. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E., et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May;22(5):1570-5. 7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. 8. Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015 Jan;136(1):130-5. 9. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–74. 10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.